Hamilton Thorne to Release Q2 2024 Financial Results on August 14, 2024


BEVERLY, Mass. and TORONTO, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Hamilton Thorne Ltd. (TSX: HTL), a leading provider of precision instruments, laboratory equipment, consumables, software and services to the Assisted Reproductive Technologies (ART), research, and cell biology markets, today announced that it will release its financial results for the three and six months ended June 30, 2024 before market open on Wednesday, August 14, 2024. The press release, with accompanying financial information, will be posted on the Company’s website at www.hamiltonthorne.ltd and on www.sedarplus.ca.

The Company’s updated investor presentation will be available on Hamilton Thorne’s website shortly after the release. The Company announced it will not be hosting a conference call.

About Hamilton Thorne Ltd. (www.hamiltonthorne.ltd)

Hamilton Thorne is a leading global provider of precision instruments, laboratory equipment, consumables, software, and services that reduce cost, increase productivity, improve results, and enable breakthroughs in Assisted Reproductive Technologies (ART), research, and cell biology markets. Hamilton Thorne markets its products and services under the Hamilton Thorne, Gynemed, Planer, Tek-Event, IVFtech, Microptic, Gynetics, and Embryotech Laboratories brands, through its growing sales force and distributors worldwide. Hamilton Thorne Ltd.’s customer base consists of fertility clinics, university research centers, animal breeding facilities, pharmaceutical companies, biotechnology companies, and other commercial and academic research establishments.

Neither the TSX, nor its regulation services provider (as that term is defined in the policies of the TSX), accepts responsibility for the adequacy or accuracy of this release.

For more information, please contact:
 
Kate Torchilin, Pres. & CEO
Hamilton Thorne Ltd. 
978-921-2050  
ir@hamiltonthorne.ltd
 Francesco Fragasso, CFO
Hamilton Thorne Ltd. 
978-921-2050 
ir@hamiltonthorne.ltd 
 Glen Akselrod
Bristol Investor Relations
905-326-1888
glen@bristolir.com 


Tags